|
|
News Breaks | | | | October 24, 2012 | | 06:33 EDT |  | ALXN | Alexion raises FY12 EPS to $1.99-$2.04 from $1.78-$1.88, consensus $1.90
Raises FY12 revenue to $1.12B-$1.13B from $1.11B-$1.13B, consensus $1.13B. | |
|
News For ALXN From The Last 14 Days Check below for free stories on ALXN the last two weeks. |
|
|
| June 19, 2013 | | 10:46 EDT |  | ALXN | Alexion mentioned as possible target for Roche in London Times
Reference Link | | | June 18, 2013 | | 08:36 EDT |  | ALXN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. | | | June 10, 2013 | | 14:38 EDT |  | ALXN | Alexion: Will not present at William Blair conference due to schedule conflict
 Subscribe for More Information | |
|
|
|
|
|
|
